Related Experiment Videos
Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering management
1Centre for Research, Prevention, and Treatment of Atherosclerosis, Hadassah University Hospital, Jerusalem, Israel.
Insights
Many Europeans have coronary heart disease (CHD) risk factors and undertreated high cholesterol. Optimal statin doses are rarely used, but ezetimibe offers a beneficial alternative for lowering LDL-C.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Coronary heart disease (CHD) remains a significant public health concern in Europe.
- Many individuals possess risk factors for CHD, yet treatment compliance is suboptimal.
- Guidelines recommend low-density lipoprotein cholesterol (LDL-C) reduction, but many patients do not achieve target levels.
Purpose of the Study:
- To highlight the challenges in hypercholesterolaemia management and LDL-C reduction in Europe.
- To discuss the underutilization of optimal statin doses and associated barriers.
- To introduce ezetimibe as a potential therapeutic option for lipid-modifying treatment.
Main Methods:
- Review of current European guidelines for CHD prevention and lipid management.
- Analysis of treatment adherence and achievement of LDL-C targets in clinical practice.
- Evaluation of the role of statins and introduction of ezetimibe as a cholesterol absorption inhibitor.
Main Results:
- A significant proportion of patients requiring pharmacotherapy for hypercholesterolaemia are undertreated.
- One-third of treated patients fail to reach recommended LDL-C target levels.
- Optimal statin doses are infrequently prescribed due to practical concerns like dosage adjustments and side effects (e.g., myalgia).
Conclusions:
- Barriers exist in achieving optimal LDL-C reduction for CHD prevention in Europe.
- Ezetimibe demonstrates clinical benefits in monotherapy or combination therapy for lipid modification.
- Further strategies are needed to improve statin utilization and patient outcomes in hypercholesterolaemia management.
Abstract:
Many individuals throughout Europe have risk factors for coronary heart disease (CHD) and are non-compliant with recommended treatments, despite guidelines for the reduction of low-density lipoprotein cholesterol (LDL-C) and the prevention of CHD. Significant numbers who should receive pharmacotherapy for hypercholesterolaemia do not, and one-third of treated patients do not achieve recommended target LDL-C levels. Optimum doses of statins, which have demonstrated undisputed efficacy in the treatment of hypercholesterolaemia in clinical trials, are seldom used; the inconvenience of dosage adjustments and safety concerns, particularly myalgia, may constitute obstacles to their optimal use for LDL-C reduction in clinical practice. Ezetimibe is the first selective cholesterol absorption inhibitor that has demonstrated clinical benefits when used as either monotherapy or in combination with other lipid-modifying agents.